Scholarlink

<p>Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell transplantation. Recent biological insights have led to a reevaluation of GVHD. It is now recognized not merely as a donor-derived immune attack, but as a complex disease characterized by the disruption of tolerance in target tissues and abnormal immune reconstitution. Therapeutic approaches are shifting from broad, nonspecific immunosuppression toward mechanism-based targeted therapies, active management of immune reconstitution, and biomarker-based risk stratification. To optimize patient outcomes, it is essential to incorporate these evolving pathophysiological mechanisms and new therapeutic strategies into clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recent advances in the pathophysiology and treatment of GVHD

  • 期刊论文

  • 发表日期：

    2026年4月26日

查看全文
  • Junichi Sugita

摘要

Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell transplantation. Recent biological insights have led to a reevaluation of GVHD. It is now recognized not merely as a donor-derived immune attack, but as a complex disease characterized by the disruption of tolerance in target tissues and abnormal immune reconstitution. Therapeutic approaches are shifting from broad, nonspecific immunosuppression toward mechanism-based targeted therapies, active management of immune reconstitution, and biomarker-based risk stratification. To optimize patient outcomes, it is essential to incorporate these evolving pathophysiological mechanisms and new therapeutic strategies into clinical practice.